top of page
GBX EVENTS Logo
CGTI.png

8th Annual Cell & Gene Therapy Innovation Leaders Summit 2025

12th & 13th February 2025
Marina Bay Sands, Singapore

Co-Located with 17th Bio Innovation Leaders Summit

CGTI ATTENDEES

SVP and Global Head of Biotech at Bayer Pharmaceuticals

Jens H. Vogel

​Dorothee Ambrosius

Head of CMC Strategy Biologicals at Boehringer Ingelheim

Jesse McCool

Co-Founder and CEO at Wheeler Bio

Angela Vollstedt

Global Director, Cell & Gene Therapies Portfolio Management at Novartis

Uwe Gottschalk

Operating Partner at Keensight Capital

DSCF7028_edited.jpg
Two days of powerful talks from CXOs who are pioneering next-generation curative therapies

12th & 13th February 2025

Marina Bay Sands, Singapore TBC

CGTI green logo.png

"For the patients, we must do better."

The 8th Annual Cell and Gene Therapy Innovation Summit is an exclusive in person only gathering for up to 250 decision makers, intellectual vanguards and captains of industry.

​

With more regenerative medicine products approaching clinical testing and commercialisation, seize this opportunity to experience in person detailed insights and industry best practices from some of the most renowned CXO's driving and shaping the future of cell and gene therapy.

CGTI Speaker, speaking at The 7th Annual Cell & Gene Therapy Innovation Summit #CGTI in Barcelona Spain on 7th & 8th February 2024
CGTI Speaker, speaking at The 7th Annual Cell & Gene Therapy Innovation Summit #CGTI in Barcelona Spain on 7th & 8th February 2024
Learn more

Confirmed Speakers

Learn more

Register Interest

Catarina Leitao, MSAT Senior Engineer at 4TE - a ValGenesis Company speaking at The 7th Annual Cell & Gene Therapy Innovation Summit #CGTI 2024 which is being held in Barcelona, Soain on the 7th & 8th February 2024
Learn more

Programme

DSCF5056.jpg

The 2025 CGTI programme will focus on solving key scale-up and manufacturing challenges in cell and gene therapies. It will showcase the latest strategies to drive costs down in scale-up, R&D and manufacturing, while exploring new innovations such as automation, AI and advanced technologies. We will also identify how partnerships and navigating the emerging regulatory frameworks can lead to a successful path to commercial viability.

​

Delegates will have invaluable access to our co-located bioprocessing programme - #BILS 2025

 

We are creating moments that matter! 

DSCF6834_edited.jpg

KEY TOPICS

  • The REGENXBIO Manufacturing Innovation Center – A Strategic Capability for AAV Gene Therapy
    by REGENXBIO

  • The power of resilience: the critical ingredient to moving innovative therapies forward
    by Adverum Biotechnologies

  • The promise of mRNA: a multifunctional platform addressing different therapeutic areas
    by Moderna

  • Un Camino de Sorpresa - The pilgrimage of Engineered T cell therapy for autoimmune disease
    by Cabaletta Bio

​

DSCF6834_edited-2.jpg

VENDOR FOCUS

  • Identifying key components to ensure the commercial sustainability and growth of ATMPs

  • Logistics and supply chain

  • Bioreactor technology

  • Automation and digitalisation

  • Advanced analytical solution

  • Single-use systems

  • Viral vector development & manufacturing services

  • Liquid management systems

GBXEVENTS2024-66.jpg

Journey of a CXO 

  • Special presentations from key speakers

  • Thought-provoking lessons learnt and moments worth sharing

  • Discover their journey, their why and the destination of some of the most inspirational CXOs in the industry

  • Understand how and why pitfalls can lead to advances

  • We learn more from our failures rather than our successes

  • These moments are priceless

2025 Programme Snapshot

​SPEAKERS 2025

DSCF7533.jpg

"It's not the Destination, It's the journey."

​

PREVIOUS SPEAKERS